Literature DB >> 20558672

Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy.

Craig M McDonald1, Dawn A McDonald, Anita Bagley, Susan Sienko Thomas, Cathleen E Buckon, Eric Henricson, Alina Nicorici, Michael D Sussman.   

Abstract

In Duchenne muscular dystrophy, data directly linking changes in clinical outcome measures to patient-perceived well-being are lacking. This study evaluated the relationship between clinical outcome measures used in clinical trials of ambulatory Duchenne muscular dystrophy (Vignos functional grade, quantitative knee extension strength, timed functional performance measures, and gait velocity) and 2 health-related quality of life measures--the Pediatric Outcomes Data Collection Instrument and Pediatric Quality of Life Inventory-in 52 ambulatory Duchenne muscular dystrophy subjects and 36 controls. Those with the disease showed significant decrements in parent proxy-reported health-related quality of life measures versus controls across all domains. The Pediatric Outcomes Data Collection Instrument transfers/basic mobility and sports/ physical function and the Pediatric Quality of Life Inventory physical functioning domains had significant associations with age (and hence disease progression) and traditional clinical outcome measures employed in clinical trials of ambulatory boys with Duchenne muscular dystrophy. Selected domains of the Pediatric Outcomes Data Collection Instrument and generic Pediatric Quality of Life Inventory are potential patient-reported outcome measures for clinical trials in ambulatory individuals with the disease.

Entities:  

Mesh:

Year:  2010        PMID: 20558672      PMCID: PMC3695468          DOI: 10.1177/0883073810371509

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  46 in total

1.  Comparison of three outcomes instruments in children.

Authors:  J Pencharz; N L Young; J L Owen; J G Wright
Journal:  J Pediatr Orthop       Date:  2001 Jul-Aug       Impact factor: 2.324

2.  The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents.

Authors:  James W Varni; Christine A Limbers
Journal:  Pediatr Clin North Am       Date:  2009-08       Impact factor: 3.278

3.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.

Authors:  Jill E Mayhew; Julaine M Florence; Thomas P Mayhew; Erik K Henricson; Robert T Leshner; Robert J McCarter; Diana M Escolar
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

4.  The Pediatric Orthopaedic Society of North America pediatric orthopaedic functional health questionnaire: an analysis of normals.

Authors:  R J Haynes; E Sullivan
Journal:  J Pediatr Orthop       Date:  2001 Sep-Oct       Impact factor: 2.324

5.  The PedsQL 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making.

Authors:  James W Varni; Michael Seid; Tara Smith Knight; Karen Uzark; Ilona S Szer
Journal:  J Behav Med       Date:  2002-04

6.  The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.

Authors:  Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Gary L Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L Miller
Journal:  Muscle Nerve       Date:  2010-04       Impact factor: 3.217

7.  Reliability of 4 outcome measures in pediatric spinal muscular atrophy.

Authors:  Susan T Iannaccone; Linda S Hynan
Journal:  Arch Neurol       Date:  2003-08

8.  The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity.

Authors:  James W Varni; Tasha M Burwinkle; Michael Seid; Douglas Skarr
Journal:  Ambul Pediatr       Date:  2003 Nov-Dec

9.  The pathomechanics of gait in Duchenne muscular dystrophy.

Authors:  D H Sutherland; R Olshen; L Cooper; M Wyatt; J Leach; S Mubarak; P Schultz
Journal:  Dev Med Child Neurol       Date:  1981-02       Impact factor: 5.449

10.  Development of items designed to evaluate activity performance and participation in children and adolescents with spinal cord injury.

Authors:  Christina L Calhoun; Stephen M Haley; Anne Riley; Lawrence C Vogel; Craig M McDonald; M J Mulcahey
Journal:  Int J Pediatr       Date:  2009-10-25
View more
  22 in total

1.  Measuring quality of life in muscular dystrophy.

Authors:  Carla M Bann; Richard T Abresch; Barbara Biesecker; Kristin Caspers Conway; Chad Heatwole; Holly Peay; Peter Scal; Jonathan Strober; Karen Uzark; Jodi Wolff; Marjorie Margolis; Angela Blackwell; Natalie Street; Angela Montesanti; Julie Bolen
Journal:  Neurology       Date:  2015-02-06       Impact factor: 9.910

2.  Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.

Authors:  Rebecca J Willcocks; William D Rooney; William T Triplett; Sean C Forbes; Donovan J Lott; Claudia R Senesac; Michael J Daniels; Dah-Jyuu Wang; Ann T Harrington; Gihan I Tennekoon; Barry S Russman; Erika L Finanger; Barry J Byrne; Richard S Finkel; Glenn A Walter; H Lee Sweeney; Krista Vandenborne
Journal:  Ann Neurol       Date:  2016-02-19       Impact factor: 10.422

3.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

4.  Gait characteristics in a canine model of X-linked myotubular myopathy.

Authors:  Melissa A Goddard; Emily Burlingame; Alan H Beggs; Anna Buj-Bello; Martin K Childers; Anthony P Marsh; Valerie E Kelly
Journal:  J Neurol Sci       Date:  2014-08-29       Impact factor: 3.181

Review 5.  Measuring quality of life in children with spinal muscular atrophy: a systematic literature review.

Authors:  Shalvaree Vaidya; Stefan Boes
Journal:  Qual Life Res       Date:  2018-07-24       Impact factor: 4.147

6.  Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy.

Authors:  Holly L Peay; Ryan Fischer; Brennan Mange; Ryan S Paquin; Edward C Smith; Alesia Sadosky; Leo Russo; Valeria Ricotti; Colin Rensch; Carl Morris; Amy Strong Martin; Annie Ganot; Katherine Beaverson; Carol Mansfield
Journal:  Mol Genet Genomic Med       Date:  2021-03-23       Impact factor: 2.183

7.  Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health.

Authors:  Roxanna M Bendixen; Claudia Senesac; Donovan J Lott; Krista Vandenborne
Journal:  Health Qual Life Outcomes       Date:  2012-05-22       Impact factor: 3.186

8.  International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15-16 February 2012.

Authors:  Eugenio Mercuri; Craig McDonald; Anna Mayhew; Julaine Florence; Elena Mazzone; Flaviana Bianco; Valerie Decostre; Laurent Servais; Valeria Ricotti; Nathalie Goemans; Elizabeth Vroom
Journal:  Neuromuscul Disord       Date:  2012-07-13       Impact factor: 4.296

9.  The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.

Authors:  Erik Henricson; Richard Abresch; Jay J Han; Alina Nicorici; Erica Goude Keller; Evan de Bie; Craig M McDonald
Journal:  PLoS Curr       Date:  2013-07-08

10.  The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart W Peltz
Journal:  Muscle Nerve       Date:  2013-07-17       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.